Group 1 - Eikon Therapeutics raised $381.2 million in its IPO by issuing approximately 21.2 million shares at a price of $18 per share, which is at the upper limit of its target range of $16 to $18 [1] - The IPO market in the U.S. is showing signs of recovery in 2026, following a slowdown due to a government shutdown in October last year that delayed many companies' listing plans [1] - The company was founded in 2019 by Nobel Prize winners Eric Betzig, Xavier Darzacq, Luke Lavis, and Robert Tjian, and is currently developing multiple experimental cancer therapies [1] Group 2 - Eikon Therapeutics' stock will begin trading on Nasdaq under the ticker symbol "EIKN" [2] - The underwriters for the IPO include major financial institutions such as JPMorgan, Morgan Stanley, Bank of America Securities, Cantor, and Mizuho Securities [2] Group 3 - The company's lead candidate drug, EIK1001, is undergoing a late-stage clinical trial in combination with Merck's Keytruda for skin cancer, with interim analysis data expected to be released in the second half of 2026 [1]

Group 1 - Eikon Therapeutics raised $381.2 million in its U.S. initial public offering [1] - The company sold approximately 21.2 million shares at a price of $18 each [1]

Company Overview - Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines to address serious unmet medical needs, particularly in oncology [6] - The company aims to integrate traditional biology research with advanced engineering to expedite the development of better medicines [6] Initial Public Offering (IPO) Details - Eikon has priced its upsized initial public offering at $18.00 per share, offering a total of 21,177,600 shares, which is expected to generate approximately $381 million in gross proceeds [1] - The underwriters have a 30-day option to purchase an additional 3,176,640 shares at the same initial public offering price [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "EIKN" on February 5, 2026, with the offering expected to close on or about February 6, 2026 [2] Regulatory and Compliance Information - A registration statement on Form S-1 related to the offering has been filed with the SEC and was declared effective on January 30, 2026 [3] - The offering is being conducted solely through a prospectus that is part of the effective registration statement [4]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a star-studded biotechnology startup that raised more than $1 billion in venture funding, said Wednesday it has secured $381 million more through an initial public offering. The California biotech sold over 21 million shares at $18 apiece, far more than it initially set out to sell when it set terms for its offering last week. Shares will ...

Group 1: Recent IPOs - Last week, 15 new stocks were listed, including one direct listing company, Public Policy Holding (PPHC), which raised $50.84 million by issuing 4.15 million shares at $12.25 per share [1] - York Space System (YSS) raised $629 million by issuing 18.5 million shares at $34 per share [1] - Picpay (PICS) raised $434 million by issuing 22.86 million shares at $19 per share [1] - Ethos Technologies (LIFE) raised $200 million by issuing 10.53 million shares at $19 per share [1] Group 2: Upcoming IPOs - Jaguar Uranium Corp. plans to list on NYSE MKT with the ticker JAGU on February 3, 2026, aiming to raise up to $30 million by issuing 6 million shares at $4 to $6 per share [3][5] - VeraDermics, Inc. plans to list on NYSE with the ticker MANE on February 4, 2026, aiming to raise up to $214 million by issuing 13.35 million shares at $14 to $16 per share [8] - Eikon Therapeutics, Inc. plans to list on NASDAQ with the ticker EIKN on February 5, 2026, aiming to raise up to $318 million by issuing 17.65 million shares at $16 to $18 per share [10] - Bob's Discount Furniture, Inc. plans to list on February 5, 2026, aiming to raise up to $370 million by issuing 19.45 million shares at $17 to $19 per share, with projected revenue of $1.719 billion and a net profit of $80.7 million for the first nine months of 2025 [14] - Forgent Power Solutions, Inc. plans to list on NYSE with the ticker FPS on February 5, 2026, aiming to raise up to $1.624 billion by issuing 56 million shares at $25 to $29 per share, with revenue of $283 million and a net profit of $15.56 million for the last three months ending September 30, 2025 [18] - Once Upon a Farm, PBC plans to list on February 6, 2026, aiming to raise up to $209 million by issuing 11 million shares at $17 to $19 per share, with revenue of $177 million and a net loss of $39.76 million for the first nine months of 2025 [22] - Liftoff Mobile, Inc. plans to list on NASDAQ with the ticker LFTO on February 6, 2026, aiming to raise up to $762 million by issuing 25.4 million shares at $26 to $30 per share, with revenue of $492 million and a net loss of $25.65 million for the first nine months of 2025 [25] - Agomab Therapeutics NV plans to raise up to $213 million by issuing 12.5 million shares at $15 to $17 per share, with no revenue and a loss of $45.15 million for the first nine months of 2025 [28]

Core Viewpoint - Eikon Therapeutics is aiming for a valuation of up to $908.2 million in its upcoming U.S. initial public offering, indicating a resurgence in biotech listings [1] Company Summary - Eikon Therapeutics is a drug developer that is preparing for an initial public offering (IPO) in the U.S. market [1] - The targeted valuation of $908.2 million reflects the company's growth potential and investor interest in the biotech sector [1] Industry Summary - The biotech industry is experiencing a comeback in public listings, suggesting renewed investor confidence and market activity [1]

Table of Contents As filed with the Securities and Exchange Commission on January 28, 2026. Registration No. 333-292633 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 EIKON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Delaware 2836 84-2807586 (Primary Standard Industrial Classification Code Number) 230 Harriet ...

Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience in identifying high-quality IPO opportunities [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources including IPO filings, previews, calendars, and a comprehensive guide to IPO investing [1] Group 1 - IPO Edge offers a database of U.S. IPOs and tracks upcoming IPOs, helping investors navigate the IPO lifecycle from filing to listing [1] - The group emphasizes the importance of understanding the quiet period and lockup expiration dates in the IPO process [1]

Table of Contents As filed with the Securities and Exchange Commission on January 9, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EIKON THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 84-2807586 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Numbe ...